Sidney A. Scudder, M.D.

Clinical/Research Interests

Sidney A. Scudder directs the Infusion Center. His interests lie in the treatment of gynecologic malignancies, especially ovarian and cervical cancer, and in concurrent chemotherapy and radiation therapy for these diseases. He participates in basic and translational research with an emphasis on pharmacology and new drug development.

Title:

Professor, Director, Infusion Services, Cancer Center

Specialty:

Hematology and Oncology, Cancer, Internal Medicine

Center/Program Affiliation:

UC Davis Comprehensive Cancer Center, Women's Center for Health

Address:

UC Davis Comprehensive Cancer Center
4501 X St., Suite 3016
Sacramento, CA 95817

Alternate Address:

UC Davis Medical Group - Rocklin
550 West Ranch View Dr.
Rocklin, CA 95765

Phone:

(916) 734-5959

Education:

University of Florida College of Medicine
Gainesville, Florida
M.D. 1980

University of Florida
Gainesville, Florida
B.S. 1975

Internships:

Washington University
St. Louis, Missouri
1980-1981

Residency:

Washington University
St. Louis, Missouri
1981-1983
Internal Medicine

Fellowships:

Stanford University
Stanford, California
1985-1987
Anticancer Pharmacology

Stanford University
Stanford, California
1983-1985
Medical Oncology

Board Certifications:

American Board of Internal Medicine, Medical Oncology, 1986
American Board of Internal Medicine, 1983

Professional Memberships:

American Society of Clinical Oncology (ASCO)
Gynecologic Oncology Group, Affiliate, University of Washington
International Gynecologic Cancer Society
Medical Principal Investigator, Sacramento, California
Physicians for Social Responsibility
Public Responsibility in Medicine and Research
Society for Gynecological Oncologists
Southwest Oncology Group, Gynecology Committee and Principal Investigator
Western Association of Gynecologic Oncologists

Honors and Awards:

U.S. News and World Report Top Doctors, 2011
American Society of Clinical Oncology Travel Award, 1987
Pharmaceutical Manufacturer's Association Clinical Pharmacology Fellowship, 1985-87
Walter Oppelt Award in Pharmacology and Therapeutics, 1980
Paula Ellis Scholarship, 1980
Olive Levine, Damon Runyon and Walter Winchell Scholarship, 1978
American Cancer Society Medical Student Research Fellowships, 1977,1980
Lange Book Award, 1977

Select Recent Publications:

Garcia AA, Hirte H, Flemming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trail of the California, Chicago, and Princess Margaret Hospital Phase II consortia. Journal of Clinical Oncology, 26(1): 76-82. 2008

Morgan RJ, Synold TW, Gandara D, Muggia F, Scudder S, Reeds E, Margolin K, Raschko J, Leong L, Shibata S, Tetef M, Vasilev S, McBonigle K, Longmate J, Yen Y, Chow W, Somlo G, Carroll M, Doroshow JH. Phase II trial of carboplatin and fusional cyclosporine with alpha-interferon in recurrent ovarian cancer: a California Cancer Consortium Trial. Int J Gynecol Cancer, 17: 373-378. 2007

Elliott KS, Borowsky ME, Malka ES, Scudder SA, Leiserowitz GS, Russell AH. Long-term results of maximally agressive trimodality therapy in a high-risk subset of early-stage cervical cancer patients. Journal of Reproductive Medicine, 51(5): 383-388. 2006

Lin A, Ryu J, Harvey D, Sieracki B, Scudder S, Wun T. Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoeitin. Gynecologic Oncology, 102: 98-102. 2006

Smith HO, Jiang CS, Weiss GR, Hallum AV, Liu PY, Robinson WR, Cheng PC, Scudder SA, Markman M, Alberts DS. Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study. Int J Gynecol Cancer, 16: 298-305. 2006

Scudder SA, Liu PY, Wilczynski SP, Smith HO, Jiang C, Hallum AV 3rd, Smith GB, Hannigan EV, Markman M, Alberts DS; Southwest Oncology Group. Paclitaxel and carboplatin with amifostine in advanced, recurent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecol Oncol. 96(3):610-15. 2005

Stiff PJ, Shpall E, Liu PY, Wilczynski SP, Callander NS, Scudder SA, Jazieh A, Samlowski W, McCoy J and Alberts DS. Randomized Phase II trial of high-dose chemotherapy regimens with stem cell transplantation for the treatment of advanced ovarian cancer in first remission or chemosensitive relapse: a Southwest Oncology Group study. Gynecologic Oncology, 94: 98-106. 2005

Dalrymple JL, Russell AH, Lee SW, Scudder SA, Leiserowitz GS, Kinney WK, Smith LH. Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer, (1):110-7.2004

Martel CL, Li Y, Beckett L, Chew H, Christensen S, Davies A, Lam KS, Lau DH, Meyers FJ, O'Donnell RT, Richman CM, Scudder S, Tanaka M, Tuscano J, Welborn J, Wun T, Gandara DR, Lara PN. An evaluation of barriers to accrual in the era of legislation requiring insurance coverage of cancer clinical trial costs in California. The Cancer Journal, 10(5): 294-300. 2004

Wun T, Law L, Harvey D, Sieracki B, Scudder SA, Ryu JK. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation and erythropoietin. Cancer. 98(7):1514-20. 2003

To see if Sidney A. Scudder is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.